-
Why 2 Acadia Pharma Analysts Are Bracing For FDA Rejection Of Nuplazid In Dementia
Tuesday, March 9, 2021 - 2:43pm | 502Read More...ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) said late Monday it was notified by the Food and Drug Administration of deficiencies in its regulatory application to expand the label for pimavanserin, which goes by the brand name Nuplazid. The company is seeking approval for Nuplazid as a...
-
Acadia Stops Nuplazid Study Early After Drug Shows 'Statistically Superior Efficacy' In Dementia-Related Psychosis
Monday, September 9, 2019 - 2:33pm | 409Read More...ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) shares are soaring to their highest level in about two years following a clinical trial readout from the company. What Happened Acadia, an actively traded mid-cap biotech, said Monday that it will stop the Phase 3 HARMONY study early based on the...
-
Acadia Shares Hurting On Reports Of Nuplazid Deaths
Monday, April 9, 2018 - 1:15pm | 308Read More...ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) faded 24 percent Monday after CNN exposed the deaths of more than 700 Nuplazid patients since the drug’s June 2016 launch. The U.S. Food and Drug Administration recorded 1,860 serious cases of adverse events among Nuplazid users between 2016 and 2017...
-
H.C. Wainwright: Acadia Is More Than A One-Trick Pony
Wednesday, November 8, 2017 - 1:26pm | 309Read More...ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) on Tuesday reported second-quarter earnings, which consisted of a better than expected loss per share (53 cents versus expectations for 62 cents)and a revenue beat ($35.6 million versus expectations for $32.03 million). Sales of the company's only...
-
Acadia Continues Huge Rise Following FDA Panel Vote
Wednesday, March 30, 2016 - 7:52am | 177Read More...Shares of ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) were trading higher by more than 22 percent early Wednesday morning. A U.S. Food and Drug Administration panel voted 12-2 on Tuesday that Acadia's drug pimavanserin, a treatment for psychosis associated with Parkinson's disease,...
-
Acadia Pharmaceuticals Are Spiking
Monday, February 1, 2016 - 9:55am | 217Read More...Shares of ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) were trading higher by nearly 9 percent early Monday morning. Acadia Pharmaceuticals announced after Friday's market close that the Psychopharmacologic Drugs Advisory Committee of the U.S. Food and Drug Administration will review data...
